Cassava and its former execs settle SEC charges for ‘misleading’ Alzheimer’s drug data
Cassava Sciences and two of its former executives have reached a resolution with the SEC over charges of “misleading” investors about the strength of data …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.